Compare GSK plc (GSK) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wendys Co — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while Wendys Co trades at $7.69 (market cap $1.42B). The key difference: GSK plc is far larger — about 71.4× Wendys Co's market cap, and Wendys Co pays the higher dividend (7.53%). Which is the better fit depends on your goals.
| GSK | WEN | |
|---|---|---|
Market Cap | $101.34B | $1.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $11.33 |
52-Week Low | $36.20 | $6.17 |
Enterprise Value | $121.95B | $5.23B |
Dividend Yield | 3.49% | 7.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Wendy's (WEN) trades at $7.60, up 2.43% today, with technicals showing a bearish trend but oversold RSI signals. The stock has beaten earnings estimates for three consecutive quarters, though net income margins have declined from 9.37% in 2023 to 6.77% in 2025. Recent news highlights Project Fresh initiatives and meme-driven volatility, with a dividend yield of 7.1% based on the latest payout.
The outlook is mixed: low P/E of 9.66 and high ROE of 120.88% suggest value, but declining profitability and bearish analyst consensus (62.75% hold) signal caution. Key risks include U.S. traffic pressures and cost inflation, while potential catalysts are digital growth and China expansion. Investors face a trade-off between deep value and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
